Core Insights - Elevation Oncology is expanding its Phase 1 clinical trial for EO-3021 to include two combination cohorts targeting advanced gastric or gastroesophageal junction cancer, with dosing expected to start by the end of 2024 [4][9] - The company has entered into clinical supply agreements with Eli Lilly and GSK to evaluate EO-3021 in combination with ramucirumab and dostarlimab, respectively [4][10] - EO-3021 is designed as a differentiated antibody-drug conjugate targeting Claudin 18.2, with a favorable safety profile and potential for improved efficacy when combined with other therapies [7][16] Clinical Development Plans - The ongoing Phase 1 trial will assess EO-3021 as a monotherapy, with initial safety and efficacy data expected by mid-third quarter 2024 and further data in the first half of 2025 [6][9] - The combination cohorts will include dose escalation and expansion phases, focusing on safety and anti-tumor activity [8][9] - EO-3021 aims to provide improved outcomes in second-line settings when combined with ramucirumab and in front-line settings with dostarlimab [10] Market Opportunity - The combination cohorts are intended to address unmet medical needs in both first-line and second-line treatment settings for gastric or gastroesophageal junction cancer [3][4] - EO-3021's unique mechanism and safety profile may allow it to become a best-in-class treatment option for tumors expressing Claudin 18.2, which includes a majority of gastric and gastroesophageal junction adenocarcinomas [7][16] - The company retains exclusive rights to develop and commercialize EO-3021 outside Greater China, indicating a strategic focus on global market opportunities [11]
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer